A Message to Our Patient Advocacy Community on Bristol Myers Squibb’s Response to COVID-19
March 16, 2020
As the coronavirus (COVID-19) situation continues to evolve, Bristol Myers Squibb is taking proactive steps to protect and support the health and well-being of the patients, people and communities we serve, as well as our global workforce, while continuing to deliver the medicines our patients need.
You can read more about the precautions we are taking here, which include workplace, business travel and meetings restrictions. We are also doing our part to minimize the spread of COVID-19 in healthcare settings by limiting in-person interactions by our customer-facing personnel in the U.S. and certain other markets. We will continue to monitor the situation closely and update our guidance as appropriate.
Importantly, we are taking appropriate measures to ensure our patients continue to have access to our medicines. As part of our normal course of business, we have continuity plans in place to account for possible scenarios relating to our products or facilities. We are diligently monitoring manufacturing and supply facilities across the globe, and at this time we do not anticipate disruptions to the supply of our medicines due to COVID-19.
Patients are at the center of everything we do, and that includes in our response to COVID-19. Our hearts go out to all who are impacted by this significant public health emergency, and we extend our support and gratitude to organizations like yours that are continuing to support patients and their loved ones through these troubling times.
We understand our responsibility to patients and the communities we serve, and will continue to be guided in our actions by our values of passion, innovation, urgency, accountability, inclusion and integrity.